行情

ACOR

ACOR

阿索尔达治疗
NASDAQ

实时行情|Nasdaq Last Sale

1.730
+0.210
+13.82%
盘后: 1.730 0 0.00% 16:37 11/21 EST
开盘
1.550
昨收
1.520
最高
1.750
最低
1.490
成交量
207.21万
成交额
--
52周最高
21.13
52周最低
1.490
市值
8,309.22万
市盈率(TTM)
-0.2391
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACOR 新闻

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.12小时前
  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.1天前
  • The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
  • Benzinga.1天前
  • Acorda Therapeutics Announces Departure of President, International & General Counsel
  • Business Wire.11/12 12:00

更多

所属板块

生物技术和医学研究
-0.31%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

ACOR 简况

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
展开

Webull提供Acorda Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。